Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice

Back to Search
Print
Bookmark Trial

NCT01147874

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Modern Research Assoc. PLLC
Dallas, Texas, 75205, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

ClinicalTrial[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis, Psoriatic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject is >18 years of age at the time of consent.

- Subject has a confirmed diagnosis of plaque psoriasis by clinical judgment.

- Subject is able to read and complete questionnaires.

- Subjects planning to undergo radiographic evaluation, should not have any contraindications to MRI.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- None.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Psoriasis, Psoriatic ArthritisPrevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
NCT01147874
  1. Dallas, Texas
  2. Dallas, Texas
  3. Houston, Texas
  4. Houston, Texas
  5. Webster, Texas
  6. Seattle, Washington
  7. Brugge,
  8. Gent,
  9. Calgary, Alberta
  10. Edmonton, Alberta
  11. Edmonton, Alberta
  12. Vancouver, British Columbia
  13. Winnipeg, Manitoba
  14. Saint John's, Newfoundland and Labrador
  15. Hamilton, Ontario
  16. Hamilton, Ontario
  17. Kitchener, Ontario
  18. Markham, Ontario
  19. Toronto, Ontario
  20. Waterloo, Ontario
  21. Windsor, Ontario
  22. Windsor, Ontario
  23. Montreal, Quebec
  24. Montreal, Quebec
  25. Sherbrooke, Quebec
  26. Sherbrooke, Quebec
  27. Quebec,
  28. Quebec,
  29. Arhus C,
  30. Copenhagen NV,
  31. Hellerup,
  32. Nice Cedex 03,
  33. Paris Cedex 10,
  34. Toulouse,
  35. Berlin,
  36. Erlangen,
  37. Frankfurt/Main,
  38. Muenchen,
  39. Osnabrueck,
  40. Regensburg,
  41. Budapest,
  42. Debrecen,
  43. Miskolc,
  44. Miskolc,
  45. Szolnok,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Psoriasis, Psoriatic ArthritisStudy Evaluating Etanercept and Methotrexate in Plaque Psoriasis
NCT00161655
  1. Fredriksberg Alle, Copenhagen
  2. Gentofte Amtsygehus, Hellerup
  3. Helsinki,
  4. Tampere,
  5. Rikshospitalet, Olso
  6. Hudlegekontoret Akutten, Tromso
  7. Lakarhuset Fasta Centrum, Farsta
  8. Lakarhuset, Vallingby
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Official Title  ICMJE Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Brief Summary This is a phase 4, multicenter, randomized, non-therapeutic interventional trial in subjects with psoriasis looking for the prevalence of psoriatic arthritis. Subjects will be seen and evaluated by a dermatologist at visit 1 and by a rheumatologist at visit 2. A subset of subjects will then go on to visit 3 for imaging procedures (x-ray, MRI, and ultrasound).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Condition  ICMJE
  • Psoriasis
  • Psoriatic Arthritis
Intervention  ICMJE Procedure: lab draws and imaging
1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
Study Arms  ICMJE No Intervention: psoriatic arthritis (PsA) questionnaire
Intervention: Procedure: lab draws and imaging
Publications * Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729-735. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 18, 2012)		1013
Original Estimated Enrollment  ICMJE
 (submitted: June 17, 2010)		1000
Actual Study Completion Date  ICMJE July 2011
Actual Primary Completion Date July 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject is >18 years of age at the time of consent.
  • Subject has a confirmed diagnosis of plaque psoriasis by clinical judgment.
  • Subject is able to read and complete questionnaires.
  • Subjects planning to undergo radiographic evaluation, should not have any contraindications to MRI.

Exclusion Criteria:

  • None.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Canada,   Denmark,   France,   Germany,   Hungary,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01147874
Other Study ID Numbers  ICMJE 0881A6-4728
B1801032
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP